Brokerage firm Credit Suisse Assumes its rating on Lantheus Holdings Inc(NASDAQ:LNTH). The shares have been rated Neutral. The rating by Credit Suisse was issued on Sep 23, 2016.
In a different note, On Aug 29, 2016, Jefferies said it Maintains its rating on Lantheus Holdings Inc. In the research note, the firm Raises the price-target to $8.00 per share. The shares have been rated ‘Buy’ by the firm.
Lantheus Holdings Inc (LNTH) made into the market gainers list on Tuesdays trading session with the shares advancing 0.12% or 0.01 points. Due to strong positive momentum, the stock ended at $8.22, which is also near the day’s high of $8.59. The stock began the session at $8.07 and the volume stood at 2,16,719 shares. The 52-week high of the shares is $10.1 and the 52 week low is $1.76. The company has a current market capitalization of $250 M and it has 3,03,87,768 shares in outstanding.
Lantheus Holdings Inc(LNTH) last announced its earnings results on Aug 4, 2016 for Fiscal Year 2016 and Q2.Company reported revenue of $77.97M. Analysts had an estimated revenue of $72.66M. Earnings per share were $0.24. Analysts had estimated an EPS of $0.06.
Lantheus Holdings Inc. is engaged in developing manufacturing selling and distributing diagnostic medical imaging agents and products that assist clinicians in the diagnosis of cardiovascular and other diseases. The Company’s medical imaging agents are used to diagnose coronary artery disease congestive heart failure stroke peripheral vascular disease and other diseases. The Company’s products include contrast agents and medical radiopharmaceuticals including technetium generators. The Company’s products include DEFINITY TechneLite Xenon Xe 133 Gas Cardiolite Neurolite Thallium Tl 201 Gallium Ga 67 Gludef Quadramet and Ablavar. The Company is also engaged in developing agents such as Flurpiridaz F 18 which is a myocardial perfusion imaging agent; 18F LMI 1195 which is a cardiac neuronal imaging agent and LMI 1174 which is a vascular remodeling imaging agent.